Lutherville, Maryland Clinical Trials

A listing of Lutherville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 55 clinical trials
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF

This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).

pro-brain natriuretic peptide
diuretics
paroxysmal atrial fibrillation
atrial fibrillation
ventricular hypertrophy
Johns Hopkins Hospital
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. There are three different variants of PPA, each a relatively distinct speech and language profile. For individuals with non-fluent variant PPA (nfvPPA), a core symptom is apraxia of speech (AOS), which is defined as an …

neurodegenerative disorder
neurodegeneration
language therapy
apraxia of speech
aphasia
Johns Hopkins Hospital
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-nave patients with non-muscle invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to providing initial …

cancer
intravesical bcg
invasive bladder cancer
hormone levels
docetaxel
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

taxane
prostatic neoplasms, castration-resistant
antiandrogen therapy
cancer
antiandrogens
Johns Hopkins University
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

parkinson's disease
modafinil
datscan
alpha-synuclein
bradykinesia
John Hopkins University
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
Proton Radiation Therapy Registry

The Johns Hopkins Proton Therapy center is establishing a registry to capture the full 3D radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The goal is to have all patients treated at the proton center to be included in the registry …

Johns Hopkins Hospital
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

imiglucerase
gaucher disease
eliglustat
deficiency
Investigational Site Number 840044
 (10.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840044
 (10.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

replacement therapy
myozyme
glycogen storage disease type ii
gaa gene
deficiency
Investigational Site Number 840044
 (10.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

replacement therapy
agalsidase beta
deficiency
alpha-galactosidase
fabrazyme
Investigational Site Number 840044
 (10.0 away) Contact site
  • 0 views
  • 05 Aug, 2024
  • +136 other locations